The Roswell Park Cancer Institute (RPCI) Protocol Review and Monitoring System is under the direct responsibility of Alex A. Adjei MD, PhD, Associate Director for Clinical Research with administrative support provided by Joyce Yasko PhD, Administrative Director, and Laurie Musial RN, MS, CCRP, Administrative Co-Director. Dr. Yasko and Ms. Musial oversee daily operations of the PRMS components, which include the Clinical Research Feasibility and Prioritization Committee (CRPC), the Scientific Review Committee (SRC), the Response Review Committee (RRC), the Phase I Committee, and the Clinical Research Management System (CRMS). The CRPC was established in 2007 to enhance the process of study protocol development;to ensure that only high quality clinical research studies are performed, to optimize collaboration among RPCI investigators and to monitor RPCI resource utilization. All RPCI sponsored clinical research studies utilizing RPCI resources are reviewed at the concept stage (Investigator-Initiated) or study protocol stage (Industry Sponsored or National Cooperative Groups) to ensure a cohesive institution-wide clinical research program. CRPC approval must be obtained before a study is allowed to progress to SRC review and approval. All RPCI sponsored clinical research studies are reviewed by the SRC prior to submission to the IRB. The scope of SRC responsibilities includes review and approval or disapproval of new and ongoing clinical research studies, study amendments, monitoring reports, and corrective actions of non-accruing and slow accruing studies. The SRC reviews new studies to ensure that scientific content and study design are appropriate, that they are prioritized based on scientific resources, they are appropriately prioritized, and that there is statistical oversight in place. The RRC is charged with reviewing radiological responses of intervention studies and the Phase I Committee is charged with reviewing all aspects of institutional Phase I studies, respectively. The RRC reports outcomes to the SRC and the Data and Safety Monitoring Board, while the Phase I Committee reports findings to the IRB. The CRMS is the electronic database developed to provide management, capture and track all RPCI clinical research studies and their activity. The CRMS electronically monitors RPCI studies from initial submission, through the SRC and IRB review and approval process, through the study implementation process, until study termination. The Clinical and Protocol Data Management Services (CPDM) uses CRMS to manage over 2000 studies.

Public Health Relevance

Clinical research is essential to translating outstanding basic science into clinical care. The PRMS function ensures that only high quality;high priority cancer clinical research studies are conducted to maximize efficient and effective use of patient and Institute resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738374
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$108,756
Indirect Cost
$43,017
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki et al. (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27:679-93
Goossens, Maria E; Isa, Fatima; Brinkman, Maree et al. (2016) International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health 74:30
Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589
Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67
Sexton, Sandra; Tulowitzki, Ryan; Jones, Craig A et al. (2016) Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. Clin Exp Nephrol 20:162-8
Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
Austin, David C; Strand, Douglas W; Love, Harold L et al. (2016) NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate 76:1004-18
Rohrbach, Daniel J; Rigual, Nestor; Arshad, Hassan et al. (2016) Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma. J Biomed Opt 21:18002
Chinnam, Meenalakshmi; Wang, Xiaoling; Zhang, Xiaojing et al. (2016) Evaluating Effects of Hypomorphic Thoc1 Alleles on Embryonic Development in Rb1 Null Mice. Mol Cell Biol 36:1621-7

Showing the most recent 10 out of 1099 publications